Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Cathrine Axfors,Andreas M Schmitt,Perrine Janiaud,Janneke Van't Hooft,Sherief Abd-Elsalam,Ehab F Abdo,Benjamin S Abella,Javed Akram,Ravi K Amaravadi,Derek C Angus,Yaseen M Arabi,Shehnoor Azhar,Lindsey R Baden,Arthur W Baker,Leila Belkhir,Thomas Benfield,Marvin A H Berrevoets,Cheng-Pin Chen,Tsung-Chia Chen,Shu-Hsing Cheng,Chien-Yu Cheng,Wei-Sheng Chung,Yehuda Z Cohen,Lisa N Cowan,Olav Dalgard,Fernando F de Almeida E Val,Marcus V G de Lacerda,Gisely C de Melo,Lennie Derde,Vincent Dubee,Anissa Elfakir,Anthony C Gordon,Carmen M Hernandez-Cardenas,Thomas Hills,Andy I M Hoepelman,Yi-Wen Huang,Bruno Igau,Ronghua Jin,Felipe Jurado-Camacho,Khalid S Khan,Peter G Kremsner,Benno Kreuels,Cheng-Yu Kuo,Thuy Le,Yi-Chun Lin,Wu-Pu Lin,Tse-Hung Lin,Magnus Nakrem Lyngbakken,Colin McArthur,Bryan J McVerry,Patricia Meza-Meneses,Wuelton M Monteiro,Susan C Morpeth,Ahmad Mourad,Mark J Mulligan,Srinivas Murthy,Susanna Naggie,Shanti Narayanasamy,Alistair Nichol,Lewis A Novack,Sean M O'Brien,Nwora Lance Okeke,Léna Perez,Rogelio Perez-Padilla,Laurent Perrin,Arantxa Remigio-Luna,Norma E Rivera-Martinez,Frank W Rockhold,Sebastian Rodriguez-Llamazares,Robert Rolfe,Rossana Rosa,Helge Røsjø,Vanderson S Sampaio,Todd B Seto,Muhammad Shahzad,Shaimaa Soliman,Jason E Stout,Ireri Thirion-Romero,Andrea B Troxel,Ting-Yu Tseng,Nicholas A Turner,Robert J Ulrich,Stephen R Walsh,Steve A Webb,Jesper M Weehuizen,Maria Velinova,Hon-Lai Wong,Rebekah Wrenn,Fernando G Zampieri,Wu Zhong,David Moher,Steven N Goodman,John P A Ioannidis,Lars G Hemkens
DOI: https://doi.org/10.1038/s41467-021-22446-z
2021-04-15
Abstract:Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/ ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality has been extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses include patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11 (95% CI: 1.02, 1.20; I² = 0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I² = 0%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and there is no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.